Business Context and Reporting Period
This Form 8-K is a current report filed by PharmAthene, Inc. (not Altimmune, Inc.) on December 23, 2009, covering events occurring on December 17, 2009. The company is a Delaware corporation headquartered in Annapolis, Maryland.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and executive compensation arrangements.
Material Changes
The primary material change reported is the appointment of a new director and the associated equity compensation:
- Board Appointment: On December 17, 2009, the Board of Directors appointed Jeffrey W. Runge, M.D.
- Compensation Grant: Dr. Runge was granted a stock option to purchase 20,000 shares of common stock.
- Option Terms: The exercise price is $1.35 per share (the closing price on the NYSE Amex on December 17, 2009). The option vested immediately and expires on December 17, 2019.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items. A press release regarding the appointment was issued on December 21, 2009, and is attached as Exhibit 99.1.
Investor Verification Checklist
- Verify the correct registrant name is PharmAthene, Inc., as the input metadata incorrectly listed Altimmune, Inc.
- Confirm the vesting schedule and expiration date of the 20,000 share option granted to Dr. Runge.
- Review the attached press release (Exhibit 99.1) for additional context on Dr. Runge's qualifications and role.
- Check subsequent filings for any financial impact of this equity grant on the company's dilution or expense recognition.